by Richard Daverman, PhD
February 4, 2014 -- Cachet Pharma, a China drug and medical device distributor, signed a Term Sheet with Miraculins of Canada to distribute Miraculins’ Scout DS® Non-Invasive Diabetes Screening Test. Cachet will pay $500,000 in upfront and milestones, and it agreed to place a $15 million order upon China approval of the device. $15 million will continue to be the minimum level of sales over the five years of the contract. Miraculins will be responsible for obtaining CFDA approval of the device. More details....
Stock Symbol: (SHE: 002462) (TVE: MOM)
Help employers find you! Check out all the jobs and post your resume.
